0.285
0.00 (-1.11%)
| Previous Close | 0.289 |
| Open | 0.290 |
| Volume | 197,266 |
| Avg. Volume (3M) | 400,786 |
| Market Cap | 20,512,242 |
| Price / Sales | 35.75 |
| Price / Book | 0.300 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -14,371.05% |
| Diluted EPS (TTM) | -0.370 |
| Quarterly Revenue Growth (YOY) | -46.50% |
| Total Debt/Equity (MRQ) | 21.63% |
| Current Ratio (MRQ) | 5.32 |
| Operating Cash Flow (TTM) | -55.96 M |
| Levered Free Cash Flow (TTM) | -29.90 M |
| Return on Assets (TTM) | -30.90% |
| Return on Equity (TTM) | -33.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ovid Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 2.13 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 16.29% |
| % Held by Institutions | 57.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Avenue Partners, Lp | 31 Dec 2024 | 3,722,627 |
| Kennedy Capital Management Llc | 31 Dec 2024 | 1,545,387 |
| Sio Capital Management, Llc | 31 Dec 2024 | 1,000,000 |
| Oconnor, A Distinct Business Unit Of Ubs Asset Management Am | 31 Dec 2024 | 943,416 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 4.00 (Oppenheimer, 1,301.54%) | Buy |
| 4.00 (BTIG, 1,301.54%) | Buy | |
| Median | 4.00 (1,301.54%) | |
| Low | 3.00 (Wedbush, 951.16%) | Buy |
| Average | 3.67 (1,185.92%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 0.562 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 24 Mar 2025 | 4.00 (1,301.54%) | Buy | 0.444 |
| Wedbush | 12 Mar 2025 | 3.00 (951.16%) | Buy | 0.500 |
| Oppenheimer | 29 Jan 2025 | 4.00 (1,301.54%) | Buy | 0.741 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Apr 2025 | Announcement | Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference |
| 11 Mar 2025 | Announcement | Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results |
| 03 Mar 2025 | Announcement | Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors |
| 27 Feb 2025 | Announcement | Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference |
| 05 Feb 2025 | Announcement | Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |